SCHAUMBURG, Ill., April 8 /PRNewswire/ -- Sagent Pharmaceuticals, a privately held specialty pharmaceutical company, announced today that it has raised $40 million through two tranches of a strategic Series B financing. In this round, a $10 million investment was made by Zhejiang Hisun Pharmaceutical Co. Ltd. (Hisun), and the remaining $30 million was contributed by an unnamed China-focused private equity investment fund. To date, including this financing, Sagent has raised $153 million in equity capital.
About Sagent Pharmaceuticals
To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.
CONTACT: Investors, Ronald Pauli of Sagent Pharmaceuticals,
+1-847-908-1604; or Media, Aline Schimmel of WCG, +1-312-646-6295, for
Sagent Pharmaceuticals
Web site: http://www.SagentPharma.com/
